KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Nektar Therapeutics (NKTR) over the last 11 years, with Q4 2020 value amounting to $2.6 million.

  • Nektar Therapeutics' Current Deferred Revenue fell 6834.35% to $2.6 million in Q4 2020 from the same period last year, while for Dec 2020 it was $2.6 million, marking a year-over-year decrease of 6834.35%. This contributed to the annual value of $2.6 million for FY2020, which is 6834.35% down from last year.
  • Nektar Therapeutics' Current Deferred Revenue amounted to $2.6 million in Q4 2020, which was down 6834.35% from $3.0 million recorded in Q3 2020.
  • In the past 5 years, Nektar Therapeutics' Current Deferred Revenue registered a high of $38.0 million during Q4 2017, and its lowest value of $2.6 million during Q4 2020.
  • Moreover, its 5-year median value for Current Deferred Revenue was $16.6 million (2016), whereas its average is $17.8 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Current Deferred Revenue soared by 16456.24% in 2017, and later tumbled by 8021.88% in 2020.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Current Deferred Revenue stood at $14.4 million in 2016, then surged by 164.56% to $38.0 million in 2017, then plummeted by 35.12% to $24.6 million in 2018, then tumbled by 67.24% to $8.1 million in 2019, then tumbled by 68.34% to $2.6 million in 2020.
  • Its last three reported values are $2.6 million in Q4 2020, $3.0 million for Q3 2020, and $4.3 million during Q2 2020.